Sensus Healthcare

One in five Americans will be diagnosed with skin cancer by the age of 70. There is a growing need for educational information to support patients, caregivers, and anyone who has received a diagnosis.

That's why Sensus Healthcare today announced the launch of its educational platform, Treat Skin Cancer, to provide evidence-based facts and insights.

Read more in our press release: https://sensushealthcare.com/sensus-launches-treat-skin-cancer/

September 11, 2001. 🇺🇸

A day that changed our country forever.

Today, we remember the 2,977 lives taken too soon. We honor the firefighters, police officers, first responders, service members, and ordinary Americans who showed extraordinary courage in the face of unimaginable tragedy.

We remember the families who never got to say goodbye. We remember the heroes who ran toward danger when others were running away. And we remember a nation that, in its darkest hours, came together as one.

25 years later, we still remember.

May we never forget the lives lost, the sacrifices made, and the strength of the American spirit.

United we stood. United we remember. 🇺🇸

Our CEO Joe Sardano joined The Big Biz Show for the seventh time to talk about non-invasive treatment options for non-melanoma skin cancer!

Tune in: https://www.youtube.com/watch?v=MpY-Lt4HefQ

Joe Sardano, co-founder, chairman and CEO of Sensus Healthcare | The Big Biz Show Joe Sardano, co-founder, chairman and CEO of Sensus Healthcare, dis...

Joe Sardano, CEO of Sensus Healthcare (NASDAQ: SRTS) – Big Biz Show The Big Biz Show interviews Sensus Healthcare's CEO Joe Sardano

For decades, surgery has been the go-to standard for treating non-melanoma skin cancer and keloids. But just as modern medicine evolved beyond open bypasses and daily finger pricks, skin care has reached an innovative tipping point.

Learn more about how Superficial Radiotherapy (SRT) is changing treatment pathways for non-melanoma skin cancer:

How 2026 Code Changes Shifted SRT from Sensus Healthcare Code changes and widespread adoption are leading to SRT from Sensus Healthcare to be a standard treatment option for NMSC and keloids.

How a 4-Day Radiation Protocol After Surgery Reduces Keloid Recurrence How a 4-Day Radiation Protocol After Surgery Reduces Keloid Recurrence

From Scalpel to SRT: Impact of Innovation on the Dermatology Industry SRT technology offers a non-surgical alternative for non-melanoma skin cancer, giving patients an option to manage their care in the way that works best for them.

Joe Sardano, Co-Founder, Chairman and CEO of Sensus Healthcare | The Big Biz Show Joe Sardano, Co-Founder, Chairman and Chief Executive Officer of Se...

Today we’re excited to highlight Dr. William Posten of Advanced Dermasurgery Associates in Dallas, TX!

Dr. William Posten is a Mohs surgeon and offers non-invasive treatment options for non-melanoma skin cancers and keloids in his practice.

📍 Interested in finding a physician near you? Check out the Sensus Location Finder: https://sensushealthcare.com/location-finder

Keloid Treatment With Excision and Radiation Achieves 90% Cure Rate Keloid Treatment With Excision and Radiation Achieves 90% Cure Rate